Abemaciclib-associated Diarrhea: An Exploratory Analysis of Real-life Data

• Published in: Anticancer research Vol. 43; no. 3; pp. 1291 - 1299
• Main Authors: GEBBIA, VITTORIO, MARTORANA, FEDERICA, SANÒ, MARIA VITA, VALERIO, MARIA ROSARIA, GIOTTA, FRANCESCO, SPADA, MASSIMILIANO, PIAZZA, DARIO, CARUSO, MICHELE, VIGNERI, PAOLO
• Format: Journal Article
• Language: English
• Published: Greece 01.03.2023
• Subjects: Aged; Aminopyridines - adverse effects; Benzimidazoles - adverse effects; Breast Neoplasms - drug therapy; Diarrhea - chemically induced; Female; Humans; Abemaciclib; diet; comorbidities; diarrhea; age; polypharmacy
• DOI: 10.21873/anticanres.16276
• ISSN: 0250-7005; 1791-7530

Abemaciclib is a cyclin-dependent kinase 4/6 inhibitor approved in combination with endocrine therapy for treating hormone receptor-positive and human epidermal growth factor receptor 2-negative early and advanced breast cancer patients. The safety profile of abemaciclib is characterized by frequent gastrointestinal toxicity, especially diarrhea. Therefore, we performed an exploratory analysis of clinical factors that may be potentially associated with diarrhea in patients treated with abemaciclib plus endocrine therapy. Factors potentially predisposing to diarrhea were selected, such as age ≥70 years, concomitant medications and diseases, diet, and use of laxatives. These variables were correlated with the onset of grade 2/3 diarrhea in a cohort of patients treated with abemaciclib from advanced breast cancer. Univariate and multivariate analysis was performed. Sensitivity and specificity were tested using the ROC curve. Eighty women with advanced breast cancer were included in the study. The univariate analysis found a statistically significant correlation between grade 2/3 diarrhea and age ≥70 years, polypharmacy, and concomitant gastrointestinal diseases (p<0.05). In the multivariate analysis, the number of risk factors significantly correlated with the outcome of interest (p<0.0001). ROC analysis showed our model's 82% sensitivity and 75% specificity. Taking into account specific pre-existing factors, it is possible to estimate the risk of diarrhea in hormone receptor-positive and human epidermal growth factor receptor 2-negative - advanced breast cancer patients, candidates for abemaciclib plus endocrine therapy. In these subjects, implementing proactive prevention and adopting a dose-escalation strategy may represent practical approaches to decrease the abemaciclib toxicity burden.